Donor Funding Volatility and the Sustainability of HIV/AIDS Programmes in Sub-Saharan Africa: A Secondary Data Analysis and Policy Review
This secondary data analysis and policy review argues that the sustainability of HIV/AIDS programmes in Sub-Saharan Africa depends on transitioning from volatile donor funding to staged health-system reforms that prioritize domestic resource mobilization, service integration, and strengthened public financial management to mitigate the risks of funding shocks.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In many parts of Sub-Saharan Africa, the fight against HIV has been a story of remarkable progress. Over the last two decades, international aid from organizations like the United States government and the Global Fund has helped turn a once-fatal disease into a manageable condition for millions of people. This support paid for life-saving medicines, trained health workers, and built the laboratory systems needed to track the virus. However, this success has created a new kind of problem. Many countries have become so reliant on this outside money that their health systems are built around it. When the flow of aid changes, slows down, or stops, the entire system can wobble. The core question facing health leaders today is not just how to get more money, but how to build a system that can keep working even when the external support shifts.
A team of researchers from universities in Zambia, Cameroon, and Nigeria, along with partners from the Clinton Health Access Initiative, set out to understand this delicate balance. They did not conduct new surveys or interview patients in clinics. Instead, they performed a deep dive into existing information, combining data from government reports, international health organizations, and an unpublished master's thesis. Their goal was to look at the big picture: how do fluctuations in donor funding affect the day-to-day running of HIV programs, and what happens when countries try to take over these costs themselves? By piecing together trends in spending, health outcomes, and policy documents, they mapped out where the risks are highest and what a safe path forward might look like.
The researchers found that while outside money has been essential, the way it is currently used leaves health systems vulnerable. The danger is greatest when donor funds pay for the daily, recurring costs of running a program, such as buying antiretroviral drugs, paying for laboratory tests, or hiring community health workers. When this funding becomes uncertain, the immediate result is not just a missing budget line; it is a breakdown in the system. Medicines run out, testing stops, and health workers leave because their salaries are no longer covered. The study highlights that the impact is not felt equally everywhere. Countries with strong tax systems and the ability to manage their own money are better equipped to absorb these shocks. In contrast, nations that depend heavily on outside aid and have weaker financial management face a much higher risk of stock-outs, service interruptions, and widening gaps in who gets care.
One of the most critical insights from the analysis is that simply swapping donor money for domestic government money is not a simple switch to flip. The researchers argue that a country can increase its own spending and still fail to protect patients if the underlying systems for buying supplies, managing staff, and tracking data remain weak. For example, if a government raises taxes to pay for HIV drugs but does not fix the broken supply chain, the money may sit in a bank while clinics remain empty. The study suggests that the safest way to transition is not to rush, but to plan a staged reform. This means protecting the continuous supply of life-saving treatment first, while slowly moving the responsibility for procurement, data, and financing onto government-led platforms.
The paper identifies specific areas that are most at risk. The supply of medicines and the laboratory reagents needed to test patients are the first to suffer when funding drops. Community outreach programs, which reach people who might otherwise be missed, are also vulnerable because they are often the first to be cut when budgets tighten. The health workforce is another fragile point; many community health workers and data clerks are paid directly by donors. If that support vanishes, these workers leave, and the connection between the health system and the community is severed. The researchers note that in countries where these functions are integrated into the main public health system, the transition is smoother. Where they remain separate, vertical projects that operate outside the national system, the risk of collapse is much higher.
To move forward, the authors propose a roadmap that treats donor transition as a long-term health system reform rather than a short-term budget exercise. They suggest that governments and donors should agree on a multi-year plan that protects a minimum package of services, ensuring that no one stops taking their medication. This plan should include building up stockpiles of essential medicines, creating emergency funds, and gradually integrating HIV services into general primary healthcare. This integration must be done carefully, ensuring that clinics have the staff and supplies to handle the added work before the specialized donor support is removed.
The study also emphasizes that raising more money at home is necessary but not enough on its own. Success depends on how that money is managed. It requires strong governance, transparent spending, and a system that pools resources so that the poor and informal workers are not left behind. Donors, too, have a role to play during this transition. Instead of just paying for parallel projects, they should shift their support to help build national systems, co-financing the steps that lead to local ownership. This includes helping countries improve their ability to buy medicines in bulk, manage their health workforce, and track results.
Ultimately, the research concludes that the volatility of donor funding is a major threat to the sustainability of HIV programs in Sub-Saharan Africa. The risk is highest where external aid has become a substitute for national systems rather than a bridge to them. However, this challenge also offers an opportunity. If handled with a clear, gradual plan that prioritizes treatment continuity and strengthens domestic capacity, countries can build resilient health systems. These systems would be capable of protecting the hard-won gains against HIV, even when the global aid environment changes. The goal is not to end donor support abruptly, but to use it to create a foundation that can stand on its own.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.